ArticlePloS one2025
Investigation of biometabolites and novel antimicrobial peptides derived from promising source Cordyceps militaris and effect of non-small cell lung cancer genes computationally.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Anticancer Bioactive Peptides from Plants: Sources, Action Mechanisms, and Potential Superiority to Conventional Chemotherapy.Probiotics and antimicrobial proteins · 2026Review
- Phytochemical Profiling and Bioactivity Evaluation ofMetabolites · 2026Article
- Influence of Culture Conditions on Bioactive Compounds inFoods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mushrooms are considered one of the safe and effective medications because they have great economic importance due to countless biological properties. Cordyceps militaris contains bioactive compounds with antioxidant, antimicrobial and anti-cancerous properties. This study was projected to analyze the potentials of biometabolites and to extract antimicrobial peptides and protein from the C. militaris. An in-vitro analysis of biometabolites and antimicrobial peptides was performed to investigate their pharmacological potentials followed by quantification and characterization of extracted protein. Computational analysis on non-small cell lung cancer genes (NSCLC) was performed on quantified compounds to interpret the biometabolites from C. militaris that could be potential drug candidate molecules with high specificity and potency. A total of 34 compounds representing 100% of total detected constituents identified were identified using GCMS analysis and 20 compounds using LC-MS which showed strong biological activities. FT-IR spectroscopy manifest powerful instant peaks to have different bioactive components including carboxylic acid, phenols, amines and alkanes present in methanolic extract of C. militaris. In C. militaris, higher protein concentration was observed in 70% concentration of protein extract (500 μg/ml ± 0.025). The best antioxidant activity (% Radical scavenging activity) of methanolic extracts was 80a ± 0.03, antidiabetic activity was 37 ± 0.057 and anti-inflammatory activity was 40 ± 0.021 at 12 mg/ml. Antibacterial activity for different concentrations of Cordyceps protein and methanolic extracts was significantly (p < 0.05). Indolizine, 2-(4-methylphenyl) has most binding affinity (micromolar) and optimized properties to be selected as the lead inhibitor. It interacts favorably with the active site of RET gene of NSCLC and is neuroprotective and hepatoprotective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.